9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 89

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Progression free survival using the EORTC modified RECIST criteria.,  Overall response, duration of survival, overall survival and safety.,  ,

Interventions: MORAb-009 (Amatuximab), Pemetrexed

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: June 2011

Completion Date: January 2014

Last  Posted Date: December 11, 2015

Location: University of Alabama, Birmingham, Birmingham, Alabama, United States

Website Link: https://ClinicalTrials.gov/show/NCT00738582

Was this article helpful?
Dislike 0